Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Researchers Identify Mechanism Behind West Nile Virus-Associated Memory Loss

XTALKS VITALS NEWS

Neurons

The researchers identified sources of inflammation associated with the West Nile virus infection, which shorten the synapses responsible for transmitting messages between the neurons.

Share this!

June 24, 2016 | by Sarah Massey, M.Sc.

The mechanisms by which severe forms of West Nile virus cause mood disorders and memory loss, have been identified by researchers at the University of Colorado, Anschutz Medical Campus. The findings – which were published in the journal, Nature – could aid in the development of new treatments for the mosquito-transmitted infection.

Tweet: 50% of patients with #WestNilevirus experience #memoryloss http://ctt.ec/tabym+

According to the researchers, about half of all patients who survive a severe infection with West Nile virus, later experience learning problems, memory loss, difficulty concentrating and irritability. Until now, researchers were unclear as to how the virus caused these symptoms.

In their study, the researchers – including Dr. Bette K. DeMasters, head of neuropathology at the University of Colorado – found the virus does not have a cytotoxic effect on neurons. Instead, DeMasters and her colleagues identified sources of inflammation associated with the West Nile virus infection, which shorten the synapses responsible for transmitting messages between the neurons.

“What we found in mice, and later confirmed in humans, is that it’s not the death of cells that causes memory loss, it’s the loss of nerve cell connections,” said Dr. Kenneth Tyler, chairman of the department of neurology at the University of Colorado School of Medicine, and study co-author. “The viral infection activates microglial cells and complement pathways which are helping to fight the infection but in turn, end up destroying synapses.”



In mouse studies, the researchers noticed that West Nile virus-infected animals had more difficulty navigating their way through a maze, compared to healthy control mice. In analyzing the brain tissue collected from these infected mice, DeMasters and her team noted significant damage to the synapses in the brain.

This same phenomenon was found in brain tissue taken from humans who had died as a result of West Nile virus infection. Though relatively rare, West Nile virus is the number one cause of acute viral encephalitis in the US, according to Tyler. Individuals have a one in 100 chance of developing the severe form of the disease, once infected.

“This discovery opens up the opportunity to test therapies and medications on mice as a precursor to humans,” said Tyler. “We already have some drugs that might be good candidates for treating this condition.”


Keywords: West Nile Virus, Neurons, Memory Loss


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.